Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiaceuticsDIUXF 85 Days Sales Outstanding is 64.39 as of Dec. 2025, which is 40% below its 10-year median of 106.50. GuruFocus rates DIUXF with a GF Score™ of 85/100 and a GF Value™ of $2.71. The stock has 1 warning sign investors should review. Among 657 Healthcare Providers & Services companies, Diaceutics ranks worse than 79.45% on this metric.
Diaceutics's average Accounts Receivable for the
six
months ended in Dec. 2025 was $11.28 Mil. Diaceutics's Revenue for the
six
months ended in Dec. 2025 was $31.96 Mil.
Hence, Diaceutics's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 64.39.
The historical rank and industry rank for Diaceutics's Days Sales Outstanding or its related term are showing as below:
DIUXF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 86.77 Med: 106.5 Max: 153.11
Current: 86.77
During the past 10 years, Diaceutics's highest Days Sales Outstanding was 153.11. The lowest was 86.77. And the median was 106.50.
DIUXF's Days Sales Outstanding is ranked worse than 79.45% of 657
companies
in the Healthcare Providers & Services industry
Industry Median: 45.88
vs DIUXF: 86.77
Diaceutics's Days Sales Outstanding
declined
from Dec. 2024 (71.48) to Dec. 2025 (64.39).
Diaceutics (OTCPK:DIUXF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Diaceutics Days Sales Outstanding Related Terms
Diaceutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Diaceutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DIUXF vs VEEV, BTSG, HQY: Days Sales Outstanding Comparison
For the Health Information Services subindustry, Diaceutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics Days Sales Outstanding vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Diaceutics's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diaceutics (DIUXF) has a Days Sales Outstanding of 64.39 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Diaceutics and its competitors. This is 40% below median its historical median of 106.50. Over the past decade, Diaceutics' Days Sales Outstanding has ranged from 86.77 to 153.11. According to the industry distribution chart, Diaceutics ranks #522 out of 657 companies in the Healthcare Providers & Services industry, placing it in the top 79.5%.
Is Diaceutics' Days Sales Outstanding too high?
Diaceutics' current Days Sales Outstanding of 64.39 is 40% below median its 10-year median of 106.50. Over the past 10 years, this metric has ranged from a low of 86.77 to a high of 153.11. The Healthcare Providers & Services industry median Days Sales Outstanding is 45.88. Diaceutics' value of 64.39 is 40.3% above this industry median. Based on the distribution chart, Diaceutics ranks #522 out of 657 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Diaceutics has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' Days Sales Outstanding compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diaceutics ranks #522 out of 657 companies for Days Sales Outstanding. This places Diaceutics in the lower half of its industry. The industry median Days Sales Outstanding is 45.88. Diaceutics' value of 64.39 is 40.3% above this benchmark. Historically, Diaceutics' own Days Sales Outstanding has ranged from 86.77 to 153.11 over the past decade. While the company's 10-year median is 106.50 vs. the industry median of 45.88, Diaceutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Healthcare Providers & Services company?
The median Days Sales Outstanding among Healthcare Providers & Services companies is 45.88, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diaceutics's current Days Sales Outstanding of 64.39 is 40.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Diaceutics and its competitors. For the Healthcare Providers & Services industry, the median Days Sales Outstanding is 45.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current Days Sales Outstanding is 64.39, which is 40% below median its own 10-year median of 106.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Diaceutics (DIUXF) has a current Days Sales Outstanding of 64.39. The stock's GF Value™ is $2.71, compared to a current price of $2.00 — trading 26.2% below its estimated fair value. The current Days Sales Outstanding is 64.39, which is 40% below median its 10-year median of 106.50 and 40.3% above the Healthcare Providers & Services industry median of 45.88. Diaceutics' overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Diaceutics (DIUXF), the current Days Sales Outstanding is 64.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (DIUXF) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of $2.00 is trading 26.2% below its estimated GF Value™ of $2.71.
Key valuation signals for DIUXF:
Days Sales Outstanding: 64.39 (40% below median its 10-year median of 106.50)
GF Value™: $2.71 vs. price of $2.00 (26.2% below fair value)
Industry Position: 40.3% above the Healthcare Providers & Services median (#522 of 657)
No single metric tells the full story. See the DIUXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
85GF Score
Get the complete analysis for DIUXF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DIUXF has been successfully added to your 
